The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin.
about
Polymers influencing transportability profile of drugPrenatal endotoxemia and placental drug transport in the mouse: placental size-specific effectsKnocking down breast cancer resistance protein (Bcrp) by adenoviral vector-mediated RNA interference (RNAi) in sandwich-cultured rat hepatocytes: a novel tool to assess the contribution of Bcrp to drug biliary excretionAbsence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposureStrategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs.Multiple doses of the antimuscarinic agent solifenacin do not affect the pharmacodynamics or pharmacokinetics of warfarin or the steady-state pharmacokinetics of digoxin in healthy subjects.Drugs as P-glycoprotein substrates, inhibitors, and inducers.Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir.Pharmacogenetics in diverse ethnic populations--implications for drug discovery and development.Identifying candidate causal variants responsible for altered activity of the ABCB1 multidrug resistance gene.MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males.Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoproteinDrug-drug interactions of antifungal agents and implications for patient care.Endocrine and metabolic regulation of renal drug transporters.Steroid biosynthesis and renal excretion in human essential hypertension: association with blood pressure and endogenous ouabain.Drug-drug interactions involving membrane transporters in the human kidney.Natural and synthetic polymers as inhibitors of drug efflux pumps.Marinobufagenin enhances cardiac contractility in mice with ouabain-sensitive alpha1 Na+-K+-ATPase.Exposure-response relationships and drug interactions of sirolimusPharmacokinetic Interactions Between Isavuconazole and the Drug Transporter Substrates Atorvastatin, Digoxin, Metformin, and Methotrexate in Healthy Subjects.Secondary Metabolites from Plants Inhibiting ABC Transporters and Reversing Resistance of Cancer Cells and Microbes to Cytotoxic and Antimicrobial Agents.New-generation efflux pump inhibitors.Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor.Inhibitory Potential of Antifungal Drugs on ATP-Binding Cassette Transporters P-Glycoprotein, MRP1 to MRP5, BCRP, and BSEP.The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin.Role of P-glycoprotein in the renal transport of dideoxynucleoside analog drugs.Expression of multidrug resistant gene (mdr-1/P-glycoprotein) in a megakaryoblastic cell line, CMK, and its enhancement during megakaryocytic differentiation.Transport of gemifloxacin, a 4th generation quinolone antibiotic, in the Caco-2 and engineered MDCKII cells, and potential involvement of efflux transporters in the intestinal absorption of the drug.Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells.Effect of quercetin on P-glycoprotein transport ability in Chinese healthy subjects.Adducin- and ouabain-related gene variants predict the antihypertensive activity of rostafuroxin, part 2: clinical studies.Functional G1199A ABCB1 polymorphism may have an effect on cyclosporine blood concentration in renal transplanted patients.Verapamil metabolites: potential P-glycoprotein-mediated multidrug resistance reversal agents.Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol.Expression and localization of P-glycoprotein in human heart: effects of cardiomyopathy.Different transport activity of human triallelic MDR1 893Ala/Ser/Thr variant and its association with herb extracts.Erratum to: Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor.A pharmacokinetic interaction study of ticagrelor and digoxin in healthy volunteers.Effect of repeated low-dose organophosphorothionate pesticide exposure on digoxin pharmacokinetics in rats; a possible interaction involving p-glycoprotein.Oral bioavailability and intestinal absorption of candesartan cilexetil: role of naringin as P-glycoprotein inhibitor.
P2860
Q26862824-BD09BC92-C4CA-48A7-9408-F5106DF7C488Q28533768-EB5AA3A9-7870-4CB0-8B86-06938108CADEQ28570070-2D316469-C446-4B50-91F4-07F1ECC65B0CQ33902161-C26962EE-F07C-4A3D-BC6F-9FCC86F82B0CQ34448305-5817197C-ABFE-4F9C-AB24-CBDE8E227E9FQ34569114-339AB06D-DC8A-43E8-852D-9E37A1FE3D21Q34627908-128BDDD8-DFBB-4746-9924-145DC5DC7C5CQ34633457-4BE5AE91-79FF-48B5-A444-ECAF1B363F3CQ34775319-4506AA4A-034A-4805-93C5-5E70FAF0D4B2Q35574195-54624BBE-543B-4DF8-A688-78E4ED42E05BQ35804210-328BE4A3-73F1-4FA6-96E9-0E0891225DFEQ35884806-2E64CA86-3C67-4C77-A136-0758D806DD70Q36283721-F956AF20-25C2-4204-9DD6-29D7B4110C83Q36335726-02B42144-80BC-4332-8D67-AABB6345554EQ36456067-9F20E71C-98F9-4139-B20E-78E9235C2F9AQ36543091-52FBB380-FF55-4823-8005-C1949B624D01Q36951710-BE26632E-8902-425E-B29D-9269B831983DQ37276192-82D7A186-1C89-4759-9675-4B77B89A894BQ37361711-2918A055-01E3-40CD-BE33-70E7A917279BQ37631841-16590C01-3372-4E19-AD6C-71272AC4D0D4Q38005689-9C931651-0CEE-43B5-8F7B-6F0146766B36Q38178317-AD207077-46A5-43C5-B065-037AE35D7581Q39247505-ACCD297C-28F6-4A8B-AD4C-62B079969DC8Q40746038-6E884A36-940A-4EED-9448-D1854658A390Q40851439-043362F3-E1AF-4284-9A93-60F4BF07D646Q40920708-DEFF3EEA-C132-42A0-9B87-8883F43F5A01Q41315434-4D4B2BEB-26FB-4686-9BB8-C2C35E60322EQ42513426-C5E5C872-687E-41CB-9CAE-7363D036D2DAQ42524059-3184DCC1-EA42-4BE8-B236-5951E4E27838Q42688103-E85BA09F-B651-4F4A-A40D-AE48D3D8827FQ42792540-E480E768-BDAB-42A3-8B46-F40912413999Q43708659-A224CB7B-CFDB-43B2-B190-9EA379290F89Q44536227-0F86B4F2-8720-4E6A-81C9-ABD274C1BB17Q46466256-0A7C2F28-7765-4FEB-93EE-CFB2264C813DQ48475143-B180895D-7A96-430F-91BB-F3813330F197Q48682180-DE41503C-F8F8-4322-9702-7AF94A30034EQ50634411-2E75C798-240C-48A0-9660-A76E7B9ECAADQ50924621-76D7A767-F3BF-4122-8EF0-A22AA5D6C6A1Q51772258-8555596C-A226-459E-A911-A1E249AA7EDBQ54681966-236A6537-6F9E-445D-A817-A40EC4F5EF80
P2860
The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh
1992年學術文章
@zh-hant
name
The MDR1 gene product, P-glyco ...... he cardiac glycoside, digoxin.
@en
The MDR1 gene product, P-glyco ...... he cardiac glycoside, digoxin.
@nl
type
label
The MDR1 gene product, P-glyco ...... he cardiac glycoside, digoxin.
@en
The MDR1 gene product, P-glyco ...... he cardiac glycoside, digoxin.
@nl
prefLabel
The MDR1 gene product, P-glyco ...... he cardiac glycoside, digoxin.
@en
The MDR1 gene product, P-glyco ...... he cardiac glycoside, digoxin.
@nl
P1476
The MDR1 gene product, P-glyco ...... he cardiac glycoside, digoxin.
@en
P2093
Silverman M
de Lannoy IA
P304
P356
10.1016/0006-291X(92)91593-F
P407
P577
1992-11-01T00:00:00Z